EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung Cancer.
- 15 July 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2501207
Abstract
Adjuvant targeted therapies and perioperative chemoimmunotherapy have made it imperative to perform molecular testing in early-stage nonsquamous (NSq) non-small cell lung cancer (NSCLC). We present a prospective clinical trial evaluating an electronic medical record (EMR)-based nudge intervention to promote timely completion of comprehensive molecular testing (cMT) in patients with early-stage NSq NSCLC. The EMBER-Lung trial prospectively enrolled patients undergoing surgical resection. The intervention included an EMR-based nudge at the time of the first postoperative visit, prompting the clinician to accept an order for cMT if NSq NSCLC histology. Following completion of cMT, if an actionable alteration was found, a reflex alert summarizing therapeutic options was sent to the patient's care team. The primary end point was the proportion of patients who underwent cMT in the real-world control and nudge intervention cohorts. Clinical characteristics and outcomes of the control and nudge intervention cohorts were compared using Pearson Chi-squared test, Fisher exact test, or Z score. Between July 2021 and November 2023, 460 patients were included (243 nudge and 217 control patients). The median age was 68.4 years, 64.3% female; 74.1% had a smoking history and mostly stage I (I/II/III; 75.9%, 14.1%, 10.0%, respectively). The proportion of patients with cMT increased in the nudge intervention (80/217, 36.9% v 197/243, 81.1%, P < .00001) across all stages (I to III). A greater proportion of patients with classical EGFR mutations and KRAS G12C mutations were detected in the nudge intervention setting (EGFR: 14/217, 6.5% v 41/243, 16.9%, P < .001; KRAS G12C: 12/217, 5.5%, v 33/243, 13.6%, P < .01). In well-matched control and nudge intervention cohorts, an EMR-based nudge after resection of early-stage NSq NSCLC was feasible and increased the proportion of patients with cMT. Future research will incorporate this earlier, at the time of biopsy, to inform neoadjuvant therapy.Keywords
This publication has 12 references indexed in Scilit:
- Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022Cancer Epidemiology, Biomarkers & Prevention, 2024
- Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.Journal of Clinical Oncology, 2024
- Alectinib in Resected ALK -Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2024
- Using nudges to promote clinical decision making of healthcare professionals: A scoping reviewPreventive Medicine, 2022
- Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2020
- Designing Nudges for Success in Health CareAMA Journal of Ethics, 2020
- The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung CancerJournal of Thoracic Oncology, 2020
- Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinibAnnals of Oncology, 2019
- A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLCJournal of Thoracic Oncology, 2018
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective AnalysisClinical Cancer Research, 2016